Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Samuel S. Blumenthal MD
Professor
Department of Medicine
Division of Nephrology

OFFICE ADDRESS:
VA Medical Center
5000 W National Ave
Milwaukee, WI 53295

CITIZENSHIP:  U.S.A.

EDUCATION:
6/1973 - Present B.A., Columbia University
6/1977 - Present M.D., New York University School of Medicine
7/1977 - 6/1978 Medical Internship
7/1978 - 6/1980 Medical Residency
7/1980 - 6/1983 Nephrology Fellowship
7/1999 - 8/2002 Masters of Science, Business Finance
Milwaukee, WI
University of Wisconsin-Milwaukee
Medical College of Wisconsin
Milwaukee, WI
Milwaukee, WI
Valhalla, NY
Westchester County Medical Center
Postgraduate Training and Fellowship Appointment:
Medical College of Wisconsin

FACULTY APPOINTMENTS:
7/1983 - 6/1990 Assistant Professor,
7/1990 - 8/2009 Associate Professor,
9/2008 - Present Professor,
Milwaukee, WI,
Medical College of Wisconsin,
Milwaukee, WI,
Department of Medicine, Division of Nephrology,
Medical College of Wisconsin,
Milwaukee, WI,
Medical College of Wisconsin,
Department of Medicine, Division of Nephrology,
Department of Medicine, Division of Nephrology,

ADMINISTRATIVE APPOINTMENTS:
2 - Present mo/yr Nephrology Inpatient Attending Rounds (FMLH),
3 - Present mo/yr Nephrology Consult Service (VA & FMLH),
7/1983 - 6/1995 Attending Staff, Department of Medicine,
7/1983 - 7/1986 Staff Physician, Renal Section,
7/1983 - Present Attending Staff, Department of Medicine,
7/1986 - Present Assistant Chief, Renal Section,
1986 - 1990 1993 Pathology Course Case Conferences and Lab,
1989 - 1990 Renal Physiology Teach - First year students,
7/1991 - Present Human Research Review Committee,
7/1991 - Present Chairman, Human Studies Subcommittee (VA),
7/1995 - 7/15/2001 Attending Staff, Department of Medicine,
1/1999 - Present Associate Medical Director of Dialysis,
1/1999 - 7/15/2001 Medical Director, Stella Jones Dialysis Unit,
7/2001 - Present Medical Director,
Milwaukee, WI,
Medical College of Wisconsin Committees (last five years):,
Medical College of Wisconsin Teaching Activities - Didactic/Clinical Teaching,
1/yr Medicine Ward Attending,
2/yr Nephrology Division Research Conference,
Shorewood Dialysis Unit,
Milwaukee, WI,
Froedtert Memorial Lutheran Hospital,
Milwaukee, WI,
Columbia Hospital,
Milwaukee, WI,
Columbia Hospital,
Milwaukee, WI,
Clement J. Zablocki VA Medical Center,
Milwaukee, WI,
Clement J. Zablocki VA Medical Center,
Milwaukee, WI,
Froedtert Memorial Lutheran Hospital,
Milwaukee, WI,
John L. Doyne Hospital,

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
American Board of Internal Medicine Certified
9/1980
None
ABIM - Nephrology Certified
11/1982
None
 
Licensure
Number Issue DateExpiration
Wisconsin License
21615
11/1/1978
10/31/2013
 
AWARDS AND HONORS:
7/1981 - 6/1982 National Kidney Foundation of Wisconsin Fellowship
7/1982 - 6/1983 National Kidney Foundation Fellowship
7/1983 - 6/1985 Associate Investigator of the Veterans Administration
7/1985 - 6/1988 Research Associate of the Veterans Administration
2002 - 2003 Best Teaching Service for the 2002/2003Academic Year
2003 - 2004 Best Teaching Service for the 2003/2004 Academic Year
2009 - 2010 MCW Outstanding Medical Student Teachers
Division of Nephrology / Department of Medicine
Medical College of Wisconsin
Division of Nephrology / Department of Medicine
Medical College of Wisconsin
Memberships in Professional and Honorary Societies:
American Federation of Clinical Research, 1982-2003
American Society of Nephrology, 1982-Present
International Society of Nephrology, 1982-Present
American College of Physicians, 1980 - Present
Regional/Local/Appointed Leadership and Committee Positions:
Member, Executive Committee Collaborative Study Group (1995-present)
Member, NAVIGATOR U.S. Steering Committee (2003-2009)
Research Grants, Contracts, Awards, Projects:
Title: "Control of Acid Secretion in Proximal Tubules."
Source: National Kidney Foundation of Wisconsin, Inc.
Role: Principal Investigator, est: 100% effort
- 7/1/1983 Dates: 7/1/1983 - 6/30/1984
Direct Funds: $3, 000 (total for all years)
Title: "Renal Acid Secretion in Metabolic Alkalosis."
Source: National Kidney Foundation of Wisconsin, Inc.
Role: Principal Investigator, est: 100% effort
- 7/1/1985 Dates: 7/1/1985 -6/30/1986
Direct Funds: $3, 000
Title: "Renal Acid Secretion and Cell Metabolism in Metabolic Alkalosis."
Source: Veterans Administration Central Office Merit Review Research Program
Role: Principal Investigator, est: 100% effort
- 7/1/1985 Dates: 7/1/1985 - 6/30/1987
Direct Funds: $36, 000
Title: "Cell pH and Growth of Renal Tubule Cell In Vitro."
Source: Veterans Administration Central Office Merit Review
Role: Principal Investigator, est.: 90% effort
- 7/1/1988 Dates: 7/1/1988 - 6/30/1991
Direct Funds: $32, 000
Title: "Cadmium, Zinc, Metallothionein and Kidney Cytotoxicity."
Source: NIEHS Award - EH1-RO1-ES0426
Role: Co-Principal Investigator, est.: 17% effort
- 7/1/1990 Dates: 7/01/1990 -6/30/1995
Direct Funds: $6, 000
Title: "Proliferative Response of Cultured Cortical Tubule Cells to Medium Acidification."
Source: National Kidney Foundation of Wisconsin, Inc.
Role: Principal Investigator, est: 100% effort
- 7/1/1988 Dates: 7/1/1988 - 6/30/1989
Direct Funds: $6, 000
Title: "Cadmium, Zinc, Metallothionein and Kidney Toxicity."
Source: NIEHS Award - EH1-RO1-ES0426
Role: Co-Principal Investigator, est.: 17% effort
- 7/1/1995 Dates: 7/01/1995 - 6/30/2000
Direct Funds: $321, 625 (Current year $60, 000)
Title: "Cadmium, Zinc, Metallothionein and Kidney Cytotoxicity."
Source: NIEHS Award - EH1-RO1-ES0426
Role: Co-Principal Investigator, est.: 17% effort
- 7/1/2000 Dates: 7/01/2000-6/30/2004
Direct Funds: $325, 000
Title: A Molecular Approach to Reduce Hyperglycemia in Diabetes
Source: BTA Collaborative Grant Program
Role: MCW Principal Investigator, est: 5% effort
- 5/1/2006 Dates: 5/1/2006-4/30/2007
CLINICL TRIALS COMPLETED
Title: "Randomized Double-Blind, Placebo Controlled, Multi-Center Phase II Clinical Trial to Evaluate the Safety and Efficacy of Auriculin Anaritide in the Treatment of Oliguric Acute Tubular Necrosis."
Source: Scios-Nova
Role: Principal Investigator, est: 5% effort
- 6/1/1996 Dates: 6/01/1996 - 7/23/1997
Direct Funds: $6, 100
Title: "Pilot Study of the Safety and Efficacy of Irbesartan in Hypertensive Type II Diabetic Subjects with Proteinuria."
Source: Bristol-Myers Squibb
Role: Principal Investigator, est: 10% effort
- 2/8/1995 Dates: 2/08/1995 - 2/08/1996
Direct Funds: $45, 608.40
Title: "Effect of Irbesartan on Mortality and Morbidity in Hypertensive Patients with Type II Diabetes and Diabetic Nephropathy."
Source: Bristol-Myers Squibb
Role: Principal Investigator, est: 10% effort
- 2/15/1996 Dates: 2/15/1996 - 12/31/2000
Direct Funds: $39, 275/yr
Title: "Anti-thrombotic Agents in the Prevention of Hemodialysis Access Thrombosis."
Source: VA Central Office Collaborative Study Program - CSP 440
Role: Participating Investigator, est: 5% effort
- 10/1/1998 Dates: 10/01/1998 - 3/01/2000
Direct Funds: $12, 930
Role: Principal Investigator, est: 5% effort
Role: Principal Investigator, est: 5% effort
Role: Principal Investigator, est: 5% effort
Title: "Open Label, Prospective, Multicenter Study to Evaluate the Rate of Adverse Events and Their Relationship to Concomitant Administration of Angiotensin Converting Enzyme Inhibitor Therapy Following Repeated Administration of Fe
Source: R&D Labs, Inc.
- 8/1/1999 Dates: 8/01/1999 - 5/01/2000
Direct Funds: $100, 000
Title: "Crossover, Randomized, Blinded, Prospective, Multicenter Clinical Evaluation of the Rate of Adverse Events to Ferrlecit in Hemodialysis Patients as Compared to Placebo and Historical Control"
Source: R&D Lab, Inc.
- 8/1/1999 Dates: 8/01/1999 - 9/01/2000
Direct Funds: $100, 000
Title: "Antihypertensive Lipid Lowering (to prevent) Heart Attack Trial (ALLHAT)."
Source: NIH
- 8/24/94 Dates: 8/24/94-3/15/2002
Direct Funds: $37, 950/yr
Title: "Valsartan Antihypertensive Long-term Use Evaluation (VALUE)"
Source: Norvartis Pharmaceutical Corporation
Role: Principal Investigator, est: 5% effort
- 5/22/98 Dates: 5/22/98 - 3/31/04
Direct Funds: 13, 000/year
Title: "A Triple-Blind, Parallel Study to Investigate the Effect of Losartan versus Atenolol on the Reduction of Morbidity and Mortality in Hypertension Patients with Left Ventricular Hypertrophy", Protocol 133-01/COZ 368.
Source: Merck & Company, Inc.
Role: Principal Investigator, est:5%
- 2/28/1996 Dates: 2/28/1996 - 11/1/2001
Direct Funds: $7, 000/year
Title: "A Study Evaluating the Initiation and Titration of Fixed Doses of Novel Erythropoiesis Stimulating Protein (NESP) Therapy in Subjects with Chronic Renal Insufficiency."
Source: Amgen, Inc.
Role: Principal Investigator, est: 5% effort
- 3/1/2000 Dates: 3/01/2000 - 3/01/2002
Direct Funds: $25, 000
Title: "Homocysteinemia in kidney and end stage renal disease (HOST)."
CSP #453
Source: VA Central Office Collaborative Study Program
Role: Participating Investigator, (5% effort)
- 7/2/2001 Dates: 7/2/2001 - 7/2/2001 - 6/2/2003
Direct Funds: $32, 000/year
Title: "The efficacy and safety of omapatrilat added to hydrochlorothiazide for the treatment of hypertension in subjects non-responsive to hydrochlorothiazide alone".
Source: Bristol-Myers Squibb
Role: Principal Investigator, est: 5% effort
- 5/24/2001 Dates: 5/24/2001 - 12/31/2002
Title: "A phase II, multi-center, double-blinded, placebo-controlled clinical study to determine the effect of DTI-0026 on the treatment of glomerulonephritis".
Source: Discovery Therapeutics, Inc.
Role: Principal Investigator, est: 5% effort
- 8/22/0 Dates: 8/22/00 - 5/1/2002.
Direct Funds: $9, 000/year
Title: "Correction of hemoglobin and outcomes in renal insufficiency (CHOIR)".
Source: Ortho Biotech Products, L.P.
Role: Principal Investigator, est: 5% effort
- 2/1/2002 Dates: 2/1/2002 - 1/31/2006
Direct Funds: $8, 400/patient
Title: "A placebo-controlled, double-blind, multicenter study to assess the efficacy and safety on an oral calcimimetic agent (AMG 073) in secondary hyperparathyroidism of chronic kidney disease (hemodialysis and peritoneal dialysis)"
Source: Amgen, Inc.
Role: Principal Investigator, est: 5% effort
- 7/15/2002 Dates: 7/15/2002 - 3/19/2003
Direct Funds: $25, 000
Title: "Randomized, double-blind study comparing Aranesp (darbepoeitin alfa) and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in the African-American subjects with chronic renal failure (CRF) rece
Source: Amgen, Inc.
Role: Principal Investigator, est: 5% effort
- 9/30/2002 Dates: 9/30/2002 - 9/30/2003
Title: "A multicenter, randomized, open-label study to compare the efficacy and safety of an oral calcimimetic agent (AMG 073) when two different vitamin D regimens are used in subjects with secondary hyperparathyroidism of end-stage r
Source: Amgen, Inc.
Role: Principal Investigator, est: 5% effort
- 3/1/2002 Dates: 3/1/2002 - 9/1/2004
Direct Funds: $20, 000
Title: "Multicenter, randomized, double-blind, placebo controlled, dose ranging study of Kremezin in patients with moderate to severe chronic renal failure (CRF)"
Source: Kureha Pharmaceuticals, Inc.
Role: Principal Investigator, est: 5% effort
- 12/1/2002 Dates: 12/1/2002 - 11/30/2003
Direct Funds: $5, 000/patient
Title: "A prospective, randomized, open-label, blinded end-point, forced-titration trial to compare Micardis Plus/Micardis Hct (telmisartan combine with hydrochlorothiazide 80 mg/1.25 mg) to Diovan Hc, for the control of mild-to-moderate hypertension in obese patients with type-2 diabetes mellitus using ambulatory blood pressure monitoring"
Source: Boehringer Ingelheim Pharmaceuticals, Inc.
Role: Principal Investigator, est: 5% effort
Dates: January 2003 - February 2004
Direct Funds: $45, 000
Title: "An exploratory, randomized, double-blind, multiple dose study of KRX-101 (sulodexide gelcaps) for the treatment of type 2 diabetic nephropathic patients with persistent microalbuminuria"
Source: Keryx Biopharmaceuticals
Role: Principal Investigator, est: 5% effort
Dates: January 2004 - January 2005
Direct Funds: $50, 000
Title: An Open Label Study of KRX-101for the Treatment of Type 1 and 2 Diabetic Nephropathic Patients with Persistent Microalbuminuria - Keryx 201
Source: Keryx Biopharmaceuticals
Role: Principal Investigator
Dates: September 04 - December 05
Direct Funds: $50, 000
Title: A Phase II Study to Evaluate the Effects of Darusentan on Safety and Efficacy
in Subjects with Resistant Systolic Hypertension Receiving Combination
Therapy With Three or More Antihypertensive Drugs, Including a Diuretic
Protocol DAR-201
Source: Myogen
Role: Principal Investigator
Dates: June 2004 - June 2006
Title: A six-week, randomized, double-blind, parallel-group, multicenter study to
evaluate the safety and efficacy of the combination of aliskiren 150 mg and
- 5 amlodipine 5 mg compared to amlodipine 5 mg and 10 mg in hypertensive
patients not adequately responsive to amlodipine 5 mg
Source: Novartis Pharmaceuticals, Inc.
Role: Principal Investigator
Dates: June 2005 - June 2006
Direct Funds: $52, 075
Title: Irbesartan Vs Placebo in Combination with Ramipril for Treatment of
Albuminuria in Subjects at Elevated Cardiovascular Risk, CV131169
Source: Bristol Myers Squibb
Role: Principal Investigator
Dates: August 2004 - August 2006
Direct Funds: $10, 000
Title: A Randomized, Double-blind, Placebo-controlled, Study to Assess the Efficacy
and Safety of Cinacalcet HCl in Chronic Kidney Disease in Subjects with
Secondary Hyperparathyroidism Not Receiving Dialysis
Source: Amgen, Inc.
Role: Principal Investigator
Dates: March 2005 - January 2007
Direct Funds: $96, 000
Title: An Open-Label, Single-arm Study to Assess the Safety of Epoetin alfa
Manufactured by a Deep Tank Technology in Subjects with Chronic Kidney
Disease Receiving Dialysis - Protocol 20040268
Source: Amgen
Role: Co Investigator
- 2005 Dates: 2005 - 2007
Direct Funds: $100, 000
Title: A Randomized, Open-Label, Study to Assess the Safety of Epoetin Alfa
Manufactured by Deep Tank Technology and Epoetin Alfa manufactured by
Roller Bottle Technology Subjects with Chronic Kidney Disease not on Dialysis
- 2004 Protocol 20040259
Source: Amgen
Role: Principal Investigator
- 2005 Dates: 2005 - 2007
Direct Funds: $92, 448
Title: "ONTARGET TRANSCEND"
Source: Boerhinger Ingelheimer Pharmaceuticals
Role: Principal Investigator, est: 5% effort
- 2001 Dates: 2001-2007
Direct Funds: $122, 500
Title: The Effect of Sulodexide in Patients with Type 2 Diabetes and Microalbuminuria
- 301 Keryx 301
Source: Keryx Biopharmaceuticals
Role: Principal Investigator
Dates: June 2005 - June 2007
Direct Funds: $ 50, 000
Title: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy - Keryx 401
Source: Keryx Biopharmaceuticals
Role: Principal Investigator
Dates: June 2005 - June 2008
Direct Funds: $60, 000
Title: A Randomized, Double-Blind, Placebo-Controlled Study of XL784 Administered Orally to Subjects with Albuminuria due to Diabetic Nephropathy.
Source: Exelixis
Role: Principal Investigator
- 2006 Dates: 2006 - 2007
Direct Funds: $120, 000
Title: Starlix® (nateglinide) protocol CDJN608B2302
"A multinational, randomized, double-blind, placebo-controlled, forced-titration, 2x2 factorial design study of the efficacy and safety of long term administration of nateglinide and valsartan in the prevention of diabetes and cardiovascular outcomes in subjects with impaired gluco
Source: Novartis Pharmaceuticals Corporation
Role: Principal Investigator, est: 5% effort
- 2002 Dates: 2002-2009
Direct Funds: $ 100, 000
Title: Amgen 20070664: A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Fixed Dose Study of AMG 223 in Subjects with Chronic Kidney Disease on Hemodialysis with Hyperphosphatemia
Source: Amgen, Inc.
Role: Principal Investigator, 5% Effort
- 2007 Dates: 2007 - 2009
Direct Funds: $22, 500
Title: A Phase III, randomized, double-blind, placebo-controlled, multi-center, withdrawal study comparing MCI-196 versus placebo following a 12-week dose titration period with MCI-196 in Chronic Kidney Disease (Stage V) Subjects on Dialysis with Hyperphosphatemia
Source: Mitsubishi Pharmaceuticals, Inc.
Role: Principal Investigator, est: 5% effort
- 2009 Dates: 2009-2010
Direct Funds: $44, 000
Role: Principal Investigator, est: 5% effort
Role: Principal Investigator, est: 5% effort
Role: Principal Investigator, est: 5% effort
Title: Protocol No. PYR-210: A randomized, double-blind, placebo-controlled, multicentered, Phase IIb study to evaluate the safety and efficacy of Pyridorine ™ (pyridoxamine dichydrochloride) in patients with nephropathy due to type II diabetes.
Source: NephroGenex, Inc.
- 2008 Dates: 2008 - 2010
Direct Funds: $42, 000
Title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2/3 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmaco-kinetics, and Pharmacodynamics of Dapagliflozin in Subjects with Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control (MB 102-029)
Source: Bristol-Myers Squibb Research and Development.
- 2009 Dates: 2009 - 2011
Direct Funds: $17, 500/patient
Title: An exploratory Phase II study to assess the effect of dapagliflozin on GFR in subjects with Type 2 diabetes who have inadequate glycemic and BP control.
Source: Bristol-Myers Squibb Research and Development (MB 102-035).
- 2009 Dates: 2009 - 2010
Direct Funds: $180, 000
Title: Novartis CLAF237E1: Multicenter Trial to Evaluate Long-Term Safety and Tolerability of Vildagliptin vs. Sitagliptin in Tupe 2 Diabetes Mellitus and Renal Insufficiency.
Source: Novartis Pharmaceuticals, Inc.
Role: Principal Investigator, 5% Effort
- 2009 Dates: 2009 -2011
Direct Funds: $60, 000
Title: APB 00108: Randomized, double-blind, placebo-controlled, dose ranging study using GENZ-644470 and sevelamer in hyperphosphatemic CKD subjects on hemodialysis.
Source: Genzyme, Inc.
Role: Principal Investigator, est: 5% effort
- 2008 Dates: 2008-2009
Direct Funds: $24, 320
Title: A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal-Disease (ESRD) Following a Two-Week Washout Period.
Source: Keryx Biopharmaceuticals
Role: Principal Investigator, 5% Effort
- 2010 Dates: 2010
Direct Funds: $45, 000
Title: Evaluation of Cinacalcet HCl Therapy to Lower CardioVascular Events, EVOLVE
Source: Amgen, Inc.
Role: Principal Investigator, 5% Effort
- 2007 Dates: 2007 - 2012
Direct Funds: $16, 000 per patient
Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease including Assessment of Quality of Life.
Source: Mitsubishi Pharmaceuticals, Inc.
Role: Principal Investigator, est: 5% effort
- 2007 Dates: 2007 - 2012
Direct Funds: $10, 000/patient
Title: CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy.
Source: VA Cooperative Trials.
Role: Principal Investigator, est: 5% effort
- 2009 Dates: 2009 - 2013
Direct Funds: $51, 000/ per year
Title: Luitpold REPAIR-IDA: Randomized Evaluation of efficacy and safety of Ferric carboxymaltose in Patients with iron deficiency Anemia and Impaired Renal function.
Source: Luitpold, Inc.
Role: Principal Investigator, 5% Effort
- 2010 Dates: 2010 - 2011
Direct Funds: $25, 000
Title: A Three-Period, 58-Week Safety and Efficacy Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal Disease (ESRD) on Dialysis.
Source: Keryx Biopharmaceuticals
Role: Principal Investigator, 5% Effort
- 2011 Dates: 2011-2012
Direct Funds: $14, 000/per patient
Title: Bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: the occurrence of renal events (BEACON).
Source: Reata Pharmaceuticals, Inc.
Role: Principal Investigator, 5% Effort
- 2011 Dates: 2011-2012
Direct Funds: $14500//per patient
Role: Principal Investigator, 5% Effort
Role: Principal Investigator, 5% Effort
Role: Principal Investigator, 5% Effort
Title: A multi-centered, randomized, double-blind, placebo-controlled, Phase IV trial to evaluate the effect of saxigliptin on the incidence of cardiovascular death, myocardial infarction or ischemic stroke in patients with type 2 diabetes (SAVOR)
Source: AstraZeneca
- 2011 Dates: 2011-2016
Direct Funds: $8000/per patient
CLINICAL TRIALS ONGOING
Title: Randomized, double-masked, placebo controlled, multi-centered Phase II study to evaluate the safety and renal efficacy of LY2382770 in patients with diabetic kidney disease due to type 1 or type 2 diabetes (H9VMCGFRF).
Source: Eli Lilly & Company
- 2011 Dates: 2011-2014
Direct Funds: $10, 000/per patient
Title: A Phase 2, randomized, double-blind, placebo-controlled, fixed-dose, parallel-group, multicenter, efficacy, and safety study of MT-9938 for treatment of uremic pruritus in subjects with end-sta, A2UNE: Protocol MT-9938-A01.
Source: Mitsubishi Tanabe Pharma Corporation
- 2013 Dates: 2013-2014
Direct Funds: $10, 000/per patient
Title: A Long-Term Safety Extension Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal Disease (ESRD) on Dialysis
Source: Keryx Biopharmaceuticals
Role: Principal Investigator, 5% Effort
- 2013 Dates: 2013-2014
Direct Funds: $6, 000/per patient
- 2011 Title: 20110226 START-CKD: Strategies Using Darbepoetin alfa to Avoid Transfusions in Chronic Kidney Disease.
Source: Amgen, Inc
Role: Principal Investigator, 5% Effort
- 2013 Dates: 2013-2016
Direct Funds: $15, 000/per patient
Title: A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 Hemodialysis Subjects With Secondary Hyperparathyroidism.
Source: Amgen, Inc
Role: Principal Investigator, 5% Effort
- 2013 Dates: 2013-2015
Direct Funds: $10, 000/per patient
Invited Lectures/Workshops/Site Visits:
Regional/Local
- 1992 Date: 1992
Meeting/Event: Invited Speaker, National Kidney Foundation of Wisconsin, Sixth Annual Professional Symposium
City, State, Country: Milwaukee, WI USA
Date: June 1993
Meeting/Event: Invited Speaker, Max-Planck Institute
City, State, County: Frankfurt, Germany
Date: June 1994
Meeting/Event: Invited Speaker, St. Francis Hospital
City, State, County: Evanston, IL USA
Date: June 1994
Meeting/Event: Invited Speaker, Trinity Lutheran Hospital
City, State, County: Kansas City, MO USA
Date: July 1994
Meeting/Event: Invited Speaker, St. Michael's Hospital
City, State, County: Stevens Point, WI USA
Date: March 1997
Meeting/Event: Invited Speaker, Christ Hospital
City, State, County: Evergreen Park, IL USA
Date: October 1997
Meeting/Event: Invited Speaker, Waukesha Memorial Hospital
City, State, County: Waukesha, WI USA
Date: June 22, 2001
Meeting/Event: Grand Rounds, Froedtert Memorial Lutheran Hospital, Medical College of Wisconsin, "Diabetic Nephropathy Update".
City, State, County: Milwaukee, WI, USA
Date: June 16, 2004
Meeting/Event: Annual Milwaukee Chapter of Association of Nephrology Nurses (ANNA) "Diabetic Nephropathy".
City, State, County: Milwaukee, WI, USA
Date: May 19, 2011
Meeting/Event: National Congress of Moldova with International Participation
"Hypertension in Terminal Renal Disease"
City, Country: Chişinau, Moldova


BIBLIOGRAPHY
Books, Chapters, and Reviews
1. Petering, D.H., Dughish, M., Huang, S., Krezoski, S., Krull, D., Lewand, D., Munoz, A., Ren, L., Venkatesh, S., Blumenthal, S., and Shaw C.F. III: Cellular metallothionein: properties of apometallothionein and the comparative toxicity of CD2+ and Cd-metallothionein, In Metallothionein IV. Klaassen, C., Editor, Birkhauser Verlag, Basal, pp. 459-468, 1998.
2. Abstracts (Presented at meetings or not subsequently published in full)
3. Blumenthal, S., Piering, W.F., and Ortiz, M.: Importance of both inflow time and type of single needle device (SND) in minimizing recirculation in single needle hemodialysis (SNHD). ASAIO Abstracts, 10: 38, 1981.
4. Blumenthal S., Ware, R., and Kleinman, J.: Na+-H+ exchange in ATP-depleted renal tubule cells. Clin. Res. 29: 775A, 1982.
5. Blumenthal S., Ware, R., and Kleinman, J.: Passive Na+-H+ exchange in renal tubule cells. Kidney Int. 21: 233, 1982.
6. Blumenthal, S., and Kleinman, J.: Membrane potential affects acid-base transport in renal tubule cells. Clin. Res. 30: 784A, 1982.
7. Blumenthal S., and Kleinman, J.: Anion selectivity alters renal tubule cell Na+-H+ exchange. Kidney Int. 23: 229, 1983.
8. Kochar, M.S., Kalbfleisch, J.H., Blumenthal, S.S., and Maierhofer, W.J.: Combined α and β blocker therapy is no better than α blocker alone in diuretic treated hypertensives. Kidney Int. 23: 171, 1983.
9. Kochar, M.S., Kalbfleisch, J.H., Blumenthal, S.S., and Maierhofer, W.J.: α blocker alone as good as a combination of α- and β- blockers alone in diuretic treated hypertensives. J. Am. Coll. Cardiol. 1: 668, 1983.
10. Blumenthal S., Ware, R., and Kleinman, J.: Role of Na+-H+ exchange in acid base disorders. Clin. Res. 31: 784A, 1983.
11. Blumenthal S., and Kleinman, J.: Membrane potential and H+ transport in renal tubule cells. Fed. Proc. 42: 303, 1983.
12. Blumenthal, S., Ortiz, M., Kleinman, J.G., and Piering, W.F.: Inflow time determines recirculation in single needle hemodialysis. Am. J. Kid. Diseases: Program and Abstracts of the National Kidney Foundation 13th Annual Scientific Meeting, 1983, p. 3.
13. Blumenthal, S., Ware, R., and Kleinman, J.: Proximal tubule Na+-H+ exchange is decreased in metabolic alkalosis. Kidney Int. 29: 363, 1984.
14. Blumenthal, S., Ware, R., and Kleinman, J.: Norepinephrine stimulates Na+-H+ exchange in proximal tubule cells. Clin. Res. 32: 442A, 1984.
15. Blumenthal, S., Lewand, D., and Kleinman, J.: Differential effects of CO2 and pH on proximal tubule cells in culture. Clin. Res. 33: 850A, 1985.
16. Blumenthal, S., Lewand, D., Cragoe, E., Jr., and Kleinman, J.: CO2 stimulates growth of proximal tubule cells in primary culture. Kidney Int. 29: 363, 1985.
17. Blumenthal, S., Lewand, D., Reetz, K., Cragoe, E., and Kleinman, J.: Cell pH regulation by proximal tubule cells in primary culture. Fed. Proc. 45: 2055, 1986.
18. Kleinman, J., Blumenthal, S., Reetz, K., and Cragoe, E., Jr.: Na+-H+ exchanger of medullary tubule cells in primary culture. Clin. Res. 34: 601A, 1986.
19. Worcester, E.M., Beshensky, A.M., Altmann, C.L., and Blumenthal, S.S.: Immunoreactive nephrocalcin and crystal growth inhibitory activity are present in human cerebrospinal fluid. Clin. Res. 36: 853A, 1988.
20. Blumenthal, S., Lewand, D., Kleinman, J., Krezoski, S., and Petering, D.: Inhibition of renal glucose uptake by cadmium: relation to cell ion contents and cell energy state. Clin. Res. 37: 485A, 1989.
21. Blumenthal, S., Lewand, D., Kleinman, J., and Petering, D.: Cadmium inhibits Na+-glucose but not Na+-amino acid co-transport in cultured tubule cells. Kid. Int. 37: 477, 1990.
22. Brandes, J.C., Piering, W.F., Beres, J.A., and Blumenthal, S.S.: Clinical outcome of CAPD predicted by urea and creatinine kinetics. J. Am. Soc. Neph. 1 (4): 384, 1990.
23. Blumenthal, S., Lewand, D., Krezoski, S., and Petering, D.: Zinc exposure prevents effects of cadmiun on Na+-glucose co-transport. Clin. Res. 39: 389A, 1991.
24. Blumenthal, S., Lewand, D., Tipnis, P., and Kleinman, J.: Effects of serum proteins on Na+-linked transport in cultured kidney cells. Clin. Res. 40: 146A, 1992.
25. Blumenthal, S., Kleinman, J., and Lewand, D.: Effect of albumin on Na+ glucose cotransport in cultured kidney cells: Greater increase with apical exposure. Abstracts of the XIIIth International Congress of Nephrology, p. 113, 1993. Presented at the XIIth International Congress of Nephrology, Jerusalem, Israel, June 13-18, 1993.
26. Blumenthal, S., Ren, L., Lewand, D., and Petering, D.: Cadmium and other metals decrease sodium-dependent glucose uptake by decreasing SGLTI mRNA. Presented at the Midwest Section of the American Federation of Clinical Research, Chicago, IL, September 28-30, 1995.
27. Blumenthal, S., Ren, L., Lewand, D., and Petering, D.: Cadmium-induced Fanconi syndrome: inhibition of transcription of specific transporter mRNA. J. Am. Soc. Neph. 7(9): 1838, 1996. Presented at the American Society of Nephrology 29th annual meeting, New Orleans, LA, November 3-6, 1996.
28. Wilmer, W.A., Hebert,L.A., Lewis, E.J., Whittier, F., Cattran, D., Levey, A., Breyer, J., Spitalewitz, S., and Blumenthal, S.: Long-term follow-up of the eight patients with diabetic nephropathy who experienced remission of nephrotic syndrome during the captopril study. J. Am. Soc. Neph. 8: 120A, 1997. Presented at the American Society of Nephrology 30th annual meeting, November 2-5, 1997.
29. Tabatabai, N.M., Blumenthal, S.S., Lewand, D.L., and Petering, D.H: Cadmium can differentially modulate the level of kidney sugar transporter mRNA. J. Am. Soc. Nephrol. 12: 806A, 2001. Presented at the American Society of Nephrology/ISN World Congress of Nephrology annual meeting, San Francisco, CA, October 13-17, 2001.
30. Tabatabai, N.M., Blumenthal, S.S., Lewand, D.L., and Petering, D.H: Mouse kidney expresses mRNA of four sodium-glucose cotransporter (SGLT) isoforms: responses to cadmium. J. Am. Soc.Nephrol. 13:66A, 2002. Presented at the American Society of Nephrology/ISM World Congress of Nephrology annual meeting, Philadelphia, PA, October 31- November 5, 2002.
31. Pohl, M.A., Blumenthal, S., Hunsicker, L.G., the Collaborative Study Group. Impact of achieved systolic blood pressure on renal function in type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 13:644A, 2002.
32. Tabatabai, N.M., Blumenthal, S.S., and Petering, D.H.: Quantitative analysis of high affinity sodium-glucose cotransporter (SGLT1) messenger RNA and its correlation with glucose uptake in cultured mouse kidney cells exposed to cadmium. Presented at the American Society of Nephrology 36th Annual Meeting & Scientific Exposition, San Diego, CA, November 12-17, 2003.
33. Tabatabai, N.M., Blumenthal, S.S., Dolan, K., and Petering.: Role of transcription factor Sp1 in modulation of mouse kidney sodium-glucose co-transporter 1 (SGLT1) gene expression to metal cadmium. J. Am. Soc. Nephrol. 15:93A, 2004. Presented at the American Society of Nephrology 37th Annual Meeting & Scientific Exposition, St. Louis, MO, October 27-November 1, 2004.
34. Reed, J., Keightly, G., Blumenthal, S., Bradley, C., LaBrecque, J., and Turner ,S.: The Control Study: Enhanced achievement of NKF-DOQI ™ bone metabolism and disease targets using cinacalcet HCL (Sensipar™). J. Am. Soc. Nephrol. 15:280A, 2004. Presented at the American Society of Nephrology 37th Annual Meeting & Scientific Exposition, St. Louis, MO, October 27-November 1, 2004.
35. Schulman, G., Agarwal, R., Acharya, M., Berl, T., Blumenthal, S., and Kopyt, N.: Kremezin® (AST-120) reduces indoxyl sulfate (IS), a profibrotic compound in patients with chronic kidney disease (CKD): results from a multicenter, randomized, double-blind study. J. Am. Soc.Nephrol. 15:335A, 2004. Presented at the American Society of Nephrology 37th Annual Meeting & Scientific Exposition, St. Louis, MO, October 27-November 1, 2004.
36. Tabatabai, N.M., Sharma, M., Blumenthal, S.S., Savin, V.J., McCarthy, E.T., and Petering D.H.: In Vivo messenger RNA expression of the kidney sodium-glucose cotransporters (SGLTs) in the diabetic Zucker rats. J. Am. Soc. Nephrol. 16:404A, 2005. Presented at the American Society of Nephrology 38th Annual Meeting & Scientific Exposition, Philadelphia, PA, November 8-13, 2005.
37. Tabatabai, N.M., Kothinti, R., Blumenthal, S.S., and Petering, D.H.: Displacement of Zn+2 in zinc finger protein Sp1 and cadmium nephrotoxicity. J. Am. Soc. Nephrol. 17:121A, 2006. Presented at the American Society of Nephrology 39th Annual Meeting & Scientific Exposition, San Diego, CA, November 14-19, 2006.
38. McCarthy, E.T., Falck, J.R., Blumenthal, S.S., and Sharma, M.: 20-Hydroxyeicosatetraenoic acid (20-HETE) protects and maintains the glomerular protein permeability barrier. J. Am. Soc. Nephrol. 17:401A, 2006. Presented at the American Society of Nephrology 39th Annual Meeting & Scientific Exposition, San Diego, CA, November 14-19, 2006.
39. Hussain, S.A., Mohyuddin, T., Lu, N., Piering, W.F., and Blumenthal, S.S.: Does frequency of physician-patient contact impact outcomes of end stage renal disease patients (ESRD) receiving dialysis. J. Am. Soc. Nephrol. 17:644A, 2006. Presented at the American Society of Nephrology 39th Annual Meeting & Scientific Exposition, San Diego, CA, November 14-19, 2006.
40. Abboud, H., Liljenquist, S., Blumenthal, S., Ervin, W., Rendell, M., Aggarwal, S.K., Mitchell B., and Williams, M.: EXACT: Evaluating the effect of XL784 on albuminuria in a clinical trial of diabetic nephropathy. J. Am. Soc. Nephrol. 18:329A, 2007. Presented at the American Society of Nephrology 40th Annual Meeting & Scientific Exposition, San Francisco, CA, November 14-19, 2007.